Cem Onal1,2, Ozan Cem Guler3, Pervin Hurmuz4, Guler Yavas5, Burak Tilki4, Ezgi Oymak6, Cagdas Yavas5, Gokhan Ozyigit4. 1. Department of Radiation Oncology, Adana Dr. Turgut Noyan Research and Treatment Center, Baskent University Faculty of Medicine, 01120, Adana, Turkey. hcemonal@hotmail.com. 2. Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkey. hcemonal@hotmail.com. 3. Department of Radiation Oncology, Adana Dr. Turgut Noyan Research and Treatment Center, Baskent University Faculty of Medicine, 01120, Adana, Turkey. 4. Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey. 5. Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkey. 6. Division of Radiation Oncology, Iskenderun Gelisim Hospital, Hatay, Turkey.
Abstract
PURPOSE: This study aimed to analyze the prognostic factors associated with overall survival (OS) and progression-free survival (PFS) in patients with bone-only metastatic renal cell carcinoma (RCC) who have five or fewer lesions treated with stereotactic body radiotherapy (SBRT). METHODS: The clinical data of 54 patients with 70 bone metastases undergoing SBRT treated between 2013 and 2020 with a dose of at least 5 Gy per fraction and a biologically effective dose (BED) of at least 90 Gy were retrospectively evaluated. RESULTS: The majority of lesions were located in the spine (57.4%) and had only one metastasis (64.8%). After a median follow-up of 22.4 months, the 1‑ and 2‑year OS rates were 84.6% and 67.3%, respectively, and median OS was 43.1 months. The 1‑ and 2‑year PFS rates and median PFS were 63.0%, 38.9%, and 15.3 months, respectively. In SBRT-treated lesions, the 1‑year local control (LC) rate was 94.9%. Age, metastasis localization, and number of fractions of SBRT were significant prognostic factors for OS in univariate analysis. In multivariate analysis, patients with spinal metastasis had better OS compared to their counterparts, and patients who received single-fraction SBRT had better PFS than those who did not. No patient experienced acute or late toxicities of grade 3 or greater. CONCLUSION: Despite excellent LC at the oligometastatic site treated with SBRT, disease progression was observed in nearly half of patients 13 months after metastasis-directed local therapy, particularly as distant disease progression other than the treated lesion, necessitating an effective systemic treatment to improve treatment outcomes.
PURPOSE: This study aimed to analyze the prognostic factors associated with overall survival (OS) and progression-free survival (PFS) in patients with bone-only metastatic renal cell carcinoma (RCC) who have five or fewer lesions treated with stereotactic body radiotherapy (SBRT). METHODS: The clinical data of 54 patients with 70 bone metastases undergoing SBRT treated between 2013 and 2020 with a dose of at least 5 Gy per fraction and a biologically effective dose (BED) of at least 90 Gy were retrospectively evaluated. RESULTS: The majority of lesions were located in the spine (57.4%) and had only one metastasis (64.8%). After a median follow-up of 22.4 months, the 1‑ and 2‑year OS rates were 84.6% and 67.3%, respectively, and median OS was 43.1 months. The 1‑ and 2‑year PFS rates and median PFS were 63.0%, 38.9%, and 15.3 months, respectively. In SBRT-treated lesions, the 1‑year local control (LC) rate was 94.9%. Age, metastasis localization, and number of fractions of SBRT were significant prognostic factors for OS in univariate analysis. In multivariate analysis, patients with spinal metastasis had better OS compared to their counterparts, and patients who received single-fraction SBRT had better PFS than those who did not. No patient experienced acute or late toxicities of grade 3 or greater. CONCLUSION: Despite excellent LC at the oligometastatic site treated with SBRT, disease progression was observed in nearly half of patients 13 months after metastasis-directed local therapy, particularly as distant disease progression other than the treated lesion, necessitating an effective systemic treatment to improve treatment outcomes.
Authors: Sarathi Kalra; Jonathan Verma; Bradley J Atkinson; Surena F Matin; Christopher G Wood; Jose A Karam; Sue-Hwa Lin; Robert L Satcher; Pheroze Tamboli; Kanishka Sircar; Priya Rao; Paul G Corn; Nizar M Tannir; Eric Jonasch Journal: Clin Genitourin Cancer Date: 2017-01-18 Impact factor: 2.872
Authors: Saeed Dabestani; Lorenzo Marconi; Fabian Hofmann; Fiona Stewart; Thomas B L Lam; Steven E Canfield; Michael Staehler; Thomas Powles; Börje Ljungberg; Axel Bex Journal: Lancet Oncol Date: 2014-10-26 Impact factor: 41.316
Authors: Emma Woodward; Satinder Jagdev; Lucy McParland; Katy Clark; Walter Gregory; Alex Newsham; Suzanne Rogerson; Kate Hayward; Peter Selby; Janet Brown Journal: Bone Date: 2010-09-18 Impact factor: 4.398
Authors: M Bianchi; M Sun; C Jeldres; S F Shariat; Q-D Trinh; A Briganti; Z Tian; J Schmitges; M Graefen; P Perrotte; M Menon; F Montorsi; P I Karakiewicz Journal: Ann Oncol Date: 2011-09-02 Impact factor: 32.976
Authors: Rana R McKay; Nils Kroeger; Wanling Xie; Jae-Lyun Lee; Jennifer J Knox; Georg A Bjarnason; Mary J MacKenzie; Lori Wood; Sandy Srinivas; Ulka N Vaishampayan; Sun-Young Rha; Sumanta K Pal; Frede Donskov; Srinivas K Tantravahi; Brian I Rini; Daniel Y C Heng; Toni K Choueiri Journal: Eur Urol Date: 2013-08-15 Impact factor: 20.096
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Viktor Grünwald; Berit Eberhardt; Axel Bex; Anne Flörcken; Thomas Gauler; Thorsten Derlin; Martin Panzica; Hans Roland Dürr; Knut Achim Grötz; Rachel H Giles; Christian von Falck; Anno Graser; Alexander Muacevic; Michael Staehler Journal: Nat Rev Urol Date: 2018-08 Impact factor: 14.432